MDM2 has become a hot topic in cancer treatment, because anti-MDM2 therapy has become a reality: we actually know of molecules that block the MDM2-p53 interaction, and thus, reestablish wild type p53 activity [6,7,8,9]. This evidence concerns the gene MDM2 and cancer.